# Back pain doctor Phoenix: judge care by daily movement *Treatment Research Made Clear | Back Pain Doctor Phoenix* > A back pain doctor Phoenix guide to what PRP studies mean and what to ask before agreeing to a back procedure. ## Better daily movement matters more than a score Look for easier walking, sleeping, bending, or driving. A lower soreness score means less if daily tasks remain hard. The change also needs to last long enough to matter. Back research often mixes people with different sore areas. One person may have nerve soreness down a leg. Another may hurt near a joint or inside a disc. ## Back studies don't give one sure PRP answer PRP starts with blood drawn from the person getting care. The blood is spun to gather more platelets, the tiny cells that help clotting. A clinician then places that prepared blood in a chosen back area. Some studies put PRP inside a disc. Others place it near a joint, and the amount of platelets differs. Results from those procedures can't be treated as one answer. First, check whether the people had soreness like yours. Then check whether walking or another daily task became easier. Less soreness doesn't mean a worn disc was rebuilt. ## If your back stays sore, require clear answers QC Kinetix offers regenerative treatments after reviewing your soreness. At this clinic, that means blood with extra clot-making cells is placed at a chosen back area without surgery. A clinician examines you and gives the care, and the clinic calls that person a medical provider. They may discuss standard or concentrated PRP. Concentrated PRP contains more clot-making cells, but it can't promise a better result. Ask which kind they propose and exactly where it would go. You don't need to read the full study. Ask what daily task might improve and when you'd notice. If the clinic won't name the back area, likely benefit, or risks, don't agree until you get a clear answer. ## Sources 1. The FDA states verbatim that stem cell products, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products have NOT been 'approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' No stem cell product is approved in the United States for any orthopedic use: the only ones with FDA approval at all are blood-forming cells derived from umbilical cord blood, approved solely for disorders of blood production, and there are currently no FDA-approved exosome products. U.S. Food and Drug Administration — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA.gov*, 2025. 2. The only double-blind randomised trial of intradiscal PRP for discogenic low back pain enrolled 47 participants (29 PRP, 18 control) and reported statistically significant improvements in pain, function and satisfaction over EIGHT WEEKS compared with a contrast-agent control. It is a small, single-centre trial, the control group was offered crossover to PRP at 8 weeks, and no disc infection, neurological injury or progressive herniation was reported. The authors themselves call the results promising and say further studies are needed to define who responds. Tuakli-Wosornu YA, Terry A, Boachie-Adjei K, et al. — [Lumbar Intradiskal Platelet-Rich Plasma (PRP) Injections: A Prospective, Double-Blind, Randomized Controlled Study.](https://pubmed.ncbi.nlm.nih.gov/26314234/). *PM&R*, 2016. DOI: 10.1016/j.pmrj.2015.08.010. 3. A 2026 systematic review and meta-analysis of 15 randomised trials (740 patients) found PRP injections reduced low back pain (SMD -1.32, 95% CI -2.06 to -0.59) and disability (SMD -1.04, 95% CI -1.66 to -0.41) versus controls out to six months. Crucially, the subgroup split went the OTHER way from the marketing: NON-discogenic pain improved consistently at every time point, while DISCOGENIC pain showed benefit only at one month and longer-term effects could not be reliably demonstrated because of high heterogeneity. The authors say the findings must be interpreted cautiously. Pei X, Liu C, Wang J, et al. — [Platelet-rich plasma therapy for low back pain: A comprehensive systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/42105106/). *Journal of Back and Musculoskeletal Rehabilitation*, 2026. DOI: 10.1177/10538127261448983. 4. A 2026 double-blind randomised superiority trial of 76 patients with facet joint syndrome found PRP was NOT superior to corticosteroid: at six months only 6 PRP patients and 5 corticosteroid patients had reached the 50% pain-improvement endpoint, and there were no statistically significant differences in pain at 3, 6 or 12 months. The authors conclude the results 'do not support the use of PRP injections for facet joint syndrome.' Geoffroy M, Beissat M, Kanagaratnam L, Ackah Miezan S, Salmon JH — [Platelet-rich plasma versus corticosteroids in facet joint syndrome: A controlled, randomized, double-blind study.](https://pubmed.ncbi.nlm.nih.gov/41183587/). *Joint Bone Spine*, 2026. DOI: 10.1016/j.jbspin.2025.106001. 5. A double-blinded randomised trial at two university spine centres, using stringent inclusion criteria (>80% relief on a diagnostic block) and fluoroscopic guidance, compared sacroiliac joint PRP with sacroiliac steroid in 26 patients. Both groups improved, but the STEROID group reported lower pain and had significantly more responders (>=50% improvement) at one and three months than the PRP group. This is the best-designed sacroiliac comparison available and it favours the cheap conventional option. Chen AS, Solberg J, Smith C, et al. — [Intra-Articular Platelet Rich Plasma vs Corticosteroid Injections for Sacroiliac Joint Pain: A Double-Blinded, Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34850180/). *Pain Medicine*, 2022. DOI: 10.1093/pm/pnab332. 6. An open-blinded-endpoint randomised trial of 40 patients compared ultrasound-guided sacroiliac PRP with methylprednisolone and found the OPPOSITE: pain was significantly lower in the PRP group at six weeks and three months, with efficacy of 90% in the PRP arm versus 25% in the steroid arm at three months. It was not double-blinded and used ultrasound rather than fluoroscopic guidance, which is exactly why it and the double-blinded trial that contradicts it must be read together. Singla V, Batra YK, Bharti N, Goni VG, Marwaha N — [Steroid vs. Platelet-Rich Plasma in Ultrasound-Guided Sacroiliac Joint Injection for Chronic Low Back Pain.](https://pubmed.ncbi.nlm.nih.gov/27677100/). *Pain Practice*, 2017. DOI: 10.1111/papr.12526. 7. A 2026 meta-analysis with trial sequential analysis pooled 10 randomised and quasi-randomised trials (392 patients) comparing PRP with corticosteroid for facet and sacroiliac joint pain. PRP did not beat steroid at one month, but did at three months (MD -1.32) and six months (MD -1.70), while disability showed no significant difference at either time point. The authors state plainly that 'current evidence remains inconclusive' and that the certainty is limited. Alatefi D, Alkabazi M, Alanzi A, et al. — [Platelet-Rich Plasma versus Corticosteroid Injections for Facet and Sacroiliac Joint Pain: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.](https://pubmed.ncbi.nlm.nih.gov/42296329/). *Pain Medicine*, 2026. DOI: 10.1093/pm/pnag072. 8. The largest randomised placebo-controlled cell-therapy trial in the lumbar spine gave 100 patients with moderate degenerative disc disease a single intradiscal injection of 6 million or 18 million allogeneic mesenchymal precursor cells with hyaluronic acid, versus hyaluronic acid vehicle or saline. The cell groups beat controls on pain and disability at various time points through 36 months - but the efficacy analysis had to be ADJUSTED for post-treatment interventions, and there was NO significant difference in modified Pfirrmann score, meaning the discs did not measurably change on imaging. The study was sponsored and funded by the product's manufacturer. Amirdelfan K, Bae H, McJunkin T, et al. — [Allogeneic mesenchymal precursor cells treatment for chronic low back pain associated with degenerative disc disease: a prospective randomized, placebo-controlled 36-month study of safety and efficacy.](https://pubmed.ncbi.nlm.nih.gov/33045417/). *The Spine Journal*, 2021. DOI: 10.1016/j.spinee.2020.10.004. 9. A systematic review of intervertebral disc therapies for non-specific chronic low back pain identified 18 eligible randomised trials, of which only ONE studied stem cells and ONE studied platelet-rich plasma - too few to pool. The only quantitative synthesis possible was for intradiscal glucocorticoid, which reduced pain at short term (SMD -1.33) but with effects that were NOT sustained and no effect on activity limitations at any time point. Daste C, Laclau S, Boisson M, et al. — [Intervertebral disc therapies for non-specific chronic low back pain: a systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/34349845/). *Therapeutic Advances in Musculoskeletal Disease*, 2021. DOI: 10.1177/1759720X211028001. 10. The 2025 ASIPP regenerative-therapy guideline for chronic low back pain - written by the specialty society that performs these procedures - grades the evidence as Level III (fair) for intradiscal PRP, Level III (fair) for intradiscal bone marrow concentrate, Level III (fair) for epidural PRP, Level IV (limited) for facet joint PRP and MSC injections, Level IV (limited) for sacroiliac joint PRP, and very low for functional-spine-unit injections. All 19 recommendations are consensus-based rather than evidence-driven, the panel names the scarcity of high-quality studies as the primary limitation, and it states that most of these therapies are not covered by commercial insurance. Manchikanti L, Navani R, Navani A, et al. — [Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP).](https://pubmed.ncbi.nlm.nih.gov/41481869/). *Pain Physician*, 2025. 11. CMS covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and then only inside an approved coverage-with-evidence-development clinical study. There is no national Medicare coverage for PRP in low back pain of any origin, and commercial plans generally follow with musculoskeletal PRP non-coverage policies. Centers for Medicare & Medicaid Services — [Autologous Platelet-rich Plasma - Coverage with Evidence Development.](https://www.cms.gov/medicare/coverage/evidence/plasma). *CMS.gov*, 2025. ## Discuss the sore area before choosing care Bring notes about your soreness, medicines, and any scan. The clinician can compare those details with your exam. You'll be able to ask which back area may be causing trouble. If your back hasn't settled, QC Kinetix can discuss non-surgical regenerative treatment options made from prepared blood. Its medical providers can explain where that material goes and what recovery involves. Call (602) 837-PAIN to arrange a visit. Schedule a free consultation: --- Help for a sore back and the next decision. Learn what can ease back soreness, when to get care, and what non-surgical choices you can discuss in Phoenix. Plain help for understanding back soreness and your choices. Back Pain Phoenix is operated by the same owners who run the QC Kinetix Phoenix-area clinics, and those owners may benefit when this publication sends a reader to their clinic team. Copyright 2026 Phoenix Backpath. Educational material for preparing questions, not a diagnosis or personal treatment plan.